Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model

سال انتشار: 1399
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 382

فایل این مقاله در 7 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_IJBMS-23-5_010

تاریخ نمایه سازی: 27 مرداد 1399

چکیده مقاله:

Objective(s): Alteration in drug metabolism is very likely in diabetes mellitus. This study assessed changes in CYP2C19 enzymatic activity in the liver using omeprazole as a probe in the animal model of type II diabetes (T2DM) before and after treatment with metformin and cinnamon.Materials and Methods: Twenty-eight male Wistar rats were randomly divided into seven groups. Fourteen days after induction of type 2 diabetic mellitus (T2DM), rats in the test group received metformin, cinnamon, and metformin plus cinnamon daily for 14 days. On day 28, rats were subjected to liver perfusion by Krebs-Henseleit buffer containing omeprazole as a CYP2C19 probe. Perfusate samples were analyzed by HPLC-UV to evaluate the activity of CYP2C19.Results: Mean metabolic ratio of omeprazole was changed from 0.091±0.005 in the control group to 0.054±0.005 in the untreated-diabetic rats. This average was increased inordinately to 0.218±0.036 in the treated rats with metformin. Interestingly, the administration of cinnamon in combination with metformin in diabetic rats caused the enzyme activity to return to (0.085±0.002) approximately the observed levels in the control group (0.091±0.005).Conclusion: Results showed that despite the suppression of the CYP2C19 enzyme activity in T2DM rats, metformin treatment could increase the enzyme activity. Simultaneous application of cinnamon and metformin can modulate the function of CYP2C19 to the observed level in the control group and make it more predictable to treat diabetes mellitus and fate of drugs that are metabolized by this enzyme.

نویسندگان

Navid Neyshaburinezhad

Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Mohammad Reza Rouini

Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Hanieh Entezari

Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

Hoda Lavasani

Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Cederbaum AI. Molecular mechanisms of the microsomal mixed function oxidases ...
  • Sychev DA, Ashraf GM, Svistunov AA, Maksimov ML, Tarasov VV, ...
  • Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance ...
  • Lee SJ. Clinical application of CYP2C19 pharmacogenetics toward more personalized ...
  • Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: ...
  • Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome ...
  • Ortiz de Montellano PR. Cytochrome P450-activated prodrugs. Future Med Chem ...
  • Hashemizadeh Z, Malek-Hosseini SA, Badiee P. Prevalence of CYP2C19 genetic ...
  • Pinto N, Dolan ME. Clinically relevant genetic variations in drug ...
  • Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in ...
  • Shah RR, Smith RL. Inflammation-induced phenoconversion of polymorphic drug metabolizing ...
  • Shah RR, Smith RL. Addressing phenoconversion: the Achilles’ heel of ...
  • Vahabzadeh M, Mohammadpour A. Effect of diabetes mellitus on the ...
  • Wu Y, Ding Y, Tanaka Y, Zhang W. Risk factors ...
  • Dostalek M, Court MH, Yan B, Akhlaghi F. Significantly reduced ...
  • Matzke GR, Frye RF, Early JJ, Straka RJ, Carson SW. ...
  • Bergheim I, Bode C, Parlesak A. Decreased expression of cytochrome ...
  • Hart SN, Cui Y, Klaassen CD, Zhong XB. Three patterns ...
  • Yang X, Zhang B, Molony C, Chudin E, Hao K, ...
  • Werner SM. Patient safety and the widespread use of herbs ...
  • Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. ...
  • Hussain MS. Patient counseling about herbal-drug interactions. Afr J Tradit ...
  • Allen RW, Schwartzman E, Baker WL, Coleman CI, Phung OJ. ...
  • Medagama AB. The glycaemic outcomes of Cinnamon, a review of ...
  • Hosseinzadeh HMH. Cinnamon effects on metabolic syndrome: a review based ...
  • Liao JC, Deng JS, Chiu CS, Hou WC, Huang SS, ...
  • Kelak JA, Cheah WL, Safii R. Patient’s decision to disclose ...
  • Mohammadi S, Nezami A, Esmaeili Z, Rouini MR, Ardakani YH, ...
  • Denisenko NP, Sychev DA, Sizova ZM, Smirnov VV, Ryzhikova KA, ...
  • Lin Y,  YW,  XH,  MW,  JY,  XY, et al. Evaluation ...
  • Szkudelski T. Streptozotocin-nicotinamide-induced diabetes in the rat. Characteristics of the ...
  • Tracy TS, Chaudhry AS, Prasad B, Thummel KE, Schuetz EG, ...
  • Shah RR, Gaedigk A. Precision medicine: does ethnicity information complement ...
  • Brewer CT, Chen T. Hepatotoxicity of herbal supplements mediated by ...
  • Kimura M, Ieiri I, Wada Y, Mamiya K, Urae A, ...
  • Schlender L, Martinez YV, Adeniji C, Reeves D, Faller B, ...
  • Eskens BJ, Zuurbier CJ, van Haare J, Vink H, van ...
  • Abdel-Razzak Z, Loyer P, Fautrel A, Gautier JC, Corcos L, ...
  • Cameron AR, Morrison VL, Levin D, Mohan M, Forteath C, ...
  • Ranasinghe P, Perera S, Gunatilake M, Abeywardene E, Gunapala N, ...
  • Hong JW, Yang GE, Kim YB, Eom SH, Lew JH, ...
  • Rao Z, Xu F, Wen T, Wang F, Sang W, ...
  • Tuzcu Z, Orhan C, Sahin N, Juturu V, Sahin K. ...
  • نمایش کامل مراجع